2019 ISAR Global Research Project
The comparative effectiveness across severe asthma biologic classes (Anti-IL5 versus Anti-IgE) in patients eligible for both therapies (FIRE)
- To describe severe asthma patients eligible for both Anti-IL5 and Anti-IgE.
- To describe and compare clinical outcomes of patients receiving Anti-IL5 or Anti-IgE versus those maintained on OCS in terms of asthma control, exacerbations, lung function.
Prof. David Price (Singapore)